Myrtelle Announces Presentation of Positive 12-month Post Treatment Data in its First-in-Human Clinical Study of rAAV-Olig001-ASPA Gene Therapy at the 2023 Cell & Gene Meeting on the Mesa held by the Alliance for Regenerative Medicine
Wakefield, Mass., October 10, 2023 – Myrtelle Inc. (“Myrtelle” or the “Company”), a gene therapy company focused on developing transformative treatments for neurodegenerative diseases…
Article Date
October 10, 2023
This article is featured on another website.
Go to article
July 14, 2026
Chime Biologics Congratulates Polpharma Biologics on Global Licensing Agreement with Teva for Ocrelizumab Biosimilar Candidate
July 14, 2026
Chime Biologics Congratulates Polpharma Biologics on Global Licensing Agreement with Teva for Ocrelizumab Biosimilar Candidate
September 1, 2026
HiRO and Differentia Biotech Forge Strategic Alliance to Redefine Clinical Trial Design Through AI-Powered Simulation
HiRO and Differentia have signed a Memorandum of Understanding establishing a framework for joint development…
September 1, 2026
HiRO and Differentia Biotech Forge Strategic Alliance to Redefine Clinical Trial Design Through AI-Powered Simulation
HiRO and Differentia have signed a Memorandum of Understanding establishing a framework for joint development…